Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
83 hedge funds and large institutions have $230M invested in Bellicum Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 16 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 19
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
2% more funds holding
Funds holding: 81 → 83 (+2)
18% less call options, than puts
Call options by funds: $2.06M | Put options by funds: $2.5M
31% less capital invested
Capital invested by funds: $334M → $230M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.55M |
| 2 |
QF
QVT Financial
New York
|
+$5.83M |
| 3 |
Morgan Stanley
New York
|
+$5.76M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.67M |
| 5 |
JP Morgan Chase
New York
|
+$4.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.7M |
| 3 |
Jennison Associates
New York
|
-$5.87M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$5.58M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$5.07M |
BLCM Hedge Fund Activity: Q3 2015 in Review
83 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2015, worth a combined $230M — down 31% from $334M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BLCM positions and 16 closed out — a net gain of 2 holders — while 32 added to existing stakes and 19 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.55M. The largest seller was RA Capital Management, cutting an estimated $13M.
- 83 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2015, up from 81 in Q2 2015.
- Funds reported $230M of Bellicum Pharmaceuticals, Inc. stock for Q3 2015, down 31% quarter-over-quarter.
- 18 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2015 and 16 closed out, a net change of +2 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2015 was Millennium Management, an estimated $8.55M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2015 was RA Capital Management, an estimated $13M sold.
Based on aggregated 13F filings for Q3 2015.